Circadian Clock Crosswalk Between Chronic Disease and Antitumor Response

Article information

Chronobiol Med. 2026;8(3):130-146
Publication date (electronic) : 2026 September 30
doi : https://doi.org/10.33069/cim.2026.0020
1Department of Pharmacology, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran
2Department of Clinical Sciences, Abadan University of Medical Sciences, Abadan, Iran
3Student Research Committee, Abadan University of Medical Sciences, Abadan, Iran
4The School of Pharmacy, Marine Pharmaceutical Science Research Center, Ahvaz University of Medical Sciences, Ahvaz, Iran
5Department of Surgery, School of Medicine, Ayatollah Taleghani Hospital, Shahid Beheshti Hospital, Abadan University of Medical Sciences, Abadan, Iran
Corresponding author: Hoda Mojiri-Forushani, PhD, Department of Pharmacology, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran. Tel: 98-6153384021, E-mail: h.mojiriforushani@abadanums.ac.ir
Received 2026 May 2; Revised 2026 May 27; Accepted 2026 August 16.

Abstract

Circadian disruption is increasingly recognized as a contributing factor in both chronic disease and impaired antitumor immunity; however, these two fields have largely evolved independently. We conducted a Scale for the Assessment of Narrative Review Articles-guided narrative review of PubMed, Scopus, and Google Scholar covering the period from 1993 through 2026, screening 550 records and critically appraising 167 eligible studies across five circadian mechanisms: immune, metabolic, oxidative-genomic, neuroendocrine, and tumor-intrinsic regulation. Core clock components, including BMAL1, CLOCK, and the Period and Cryptochrome gene families, coordinate cell-cycle progression, DNA repair, metabolic flux, and immune oscillation. Disruption of these mechanisms compromises tissue homeostasis and antitumor surveillance. Circadian misalignment promotes inflammation, oxidative stress, and metabolic dysregulation associated with cardiometabolic, neurodegenerative, and respiratory diseases, while the same mechanisms remodel the tumor microenvironment and reduce tumor-infiltrating lymphocytes in preclinical models. Clinical evidence in cancer remains preliminary and is derived largely from retrospective cohorts and clinical trials demonstrating improved treatment tolerability rather than survival benefit. Interventions that restore circadian alignment—including timed light exposure, time-restricted eating, and structured sleep schedules—have demonstrated benefits in randomized trials for selected chronic conditions, whereas cancer chronotherapy remains largely at the preclinical stage. Overall, circadian biology represents a mechanistic crosswalk linking chronic disease susceptibility with antitumor immune regulation. Future priorities include the development of standardized biomarkers of circadian disruption, prospective immunotherapy-timing trials powered to assess survival outcomes, and the expansion of chronotherapy protocols to cancer types that remain unexplored.

INTRODUCTION

Rhythm and the circadian clock are closely related but fundamentally distinct concepts, and this distinction should be clarified at the outset. Rhythm refers to the measurable daily fluctuations in physiology, cognition, and behavior that vary among individuals, as illustrated by differences in the time people naturally awaken without an alarm [1]. In contrast, the circadian clock is the biological mechanism that maintains these rhythms on an approximately 24-hour cycle, regulated primarily by light exposure and the nocturnal secretion of melatonin [2]. Additional environmental factors, including diet, physical activity, and certain pharmacological agents, can also modulate the circadian system, reflecting its sensitivity to external cues from early developmental stages onward [3].

Immune function provides one of the clearest examples of the widespread influence of the circadian clock. The abundance of circulating immune cells, together with the cytokines they secrete, fluctuates throughout the day in synchrony with the sleep–wake cycle. These oscillations are regulated partly by intrinsic molecular clocks within macrophages, natural killer cells, and lymphocytes, and partly by signals originating from the suprachiasmatic nucleus (SCN). Consequently, the relationship between the circadian clock and the immune system is bidirectional. Clock genes regulate the timing of immune surveillance, whereas immune mediators, including cytokines, provide feedback that modulates circadian timing. This reciprocal interaction helps explain why allergic responses and host defenses against bacterial toxins exhibit pronounced time-of-day variation rather than occurring uniformly throughout the day [4].

Cancer biology represents another important, although more complex, dimension of circadian regulation. Circadian disruption is thought to promote malignant transformation of normal cells, while established tumors, in turn, alter the expression and function of clock genes within both malignant cells and the surrounding microenvironment. Because this relationship is reciprocal, pharmacological modulation of specific clock genes has emerged as a promising area of investigation in oncology, with potential applications extending beyond treatment to include cancer prevention, diagnosis, and disease management [5].

The circadian clock operates at every level of biological organization, from individual cells to entire organ systems. Consequently, its disruption rarely remains confined to a single pathological condition and has been associated with a broad spectrum of adverse health outcomes [6]. Immune dysregulation represents a central component of this process. For example, in a clinical cohort of patients with chronic endogenous hypercortisolism, circadian disruption significantly impaired the normal daily oscillation of immune activity [7], providing a specific illustration of the broader association between circadian misalignment and compromised immune function that contributes to the development of chronic disease [8]. Cardiometabolic, neurodegenerative, respiratory, and cancer-related disorders have all been linked to circadian disruption, although the underlying mechanisms have generally been investigated within disease-specific fields rather than through an integrated perspective.

This review integrates these previously separate lines of evidence to examine how a unified mechanistic framework can explain the relationship between circadian disruption, chronic disease, and cancer. Specifically, we propose five interconnected mechanistic axes that underlie this relationship: inflammatory and immune signaling, metabolic regulation, oxidative stress and genome maintenance, neuroendocrine regulation, and tumor-intrinsic circadian mechanisms that become established following malignant transformation. Figure 1 illustrates how these five axes connect circadian disruption to both chronic disease and impaired antitumor immunity, and the subsequent sections are organized according to this conceptual framework rather than by individual organ systems. Throughout the review, distinctions between preclinical, retrospective, and prospective clinical evidence are explicitly maintained to accurately reflect the strength of the available evidence rather than presenting the findings as equally established.

Figure 1.

Circadian disruption as a common mechanistic framework for chronic disease and cancer. ALAN, artificial light at night; ROS, reactive oxygen species; HPA, hypothalamic–pituitary–adrenal.

METHODS

This narrative review was conducted in accordance with the Scale for the Assessment of Narrative Review Articles framework. From the outset, the scope of the review was defined by the crosswalk concept that underpins this paper, focusing on circadian mechanisms that link chronic disease pathogenesis with antitumor immunity rather than reviewing each field independently.

A comprehensive literature search was performed in PubMed, Scopus, and Google Scholar to identify peer-reviewed articles published in English between 1993 and 2026. The search strategy combined free-text keywords and Medical Subject Headings related to circadian clock, chronic disease, cancer, cardiovascular disease, osteoarthritis, diabetes mellitus, Alzheimer’s disease, tumor, and antitumor response, using Boolean operators (AND, OR, and NOT) to optimize the balance between sensitivity and specificity. In addition, the reference lists of relevant review articles and primary studies identified through the database search were manually screened to retrieve eligible publications that might not have been captured through the electronic search strategy.

Studies were considered eligible if they reported original in vitro, in vivo, or clinical research, or if they provided a mechanistically detailed review addressing circadian biology in relation to at least one of the five mechanistic axes examined in this review: inflammatory and immune signaling, metabolic regulation, oxidative stress and genomic stability, neuroendocrine regulation, or tumor-intrinsic circadian biology. Eligible studies were required to have direct relevance to chronic disease pathogenesis, antitumor immune responses, or both. Studies were excluded if they consisted solely of abstracts, commentaries, editorials, or conference proceedings without an accessible full text, focused exclusively on sleep physiology without addressing circadian mechanisms, or lacked clear relevance to human disease or the mechanistic pathways examined in this review.

Given that the strength of evidence varies considerably across this field, all eligible studies were further classified according to their level of evidence during the appraisal process. Specifically, studies were categorized as mechanistic or in vitro investigations, preclinical animal studies, retrospective or observational human studies, or prospective and randomized clinical trials. This classification is explicitly maintained throughout the review whenever individual findings are discussed, rather than being left to the reader’s interpretation.

The combined database search and manual reference screening identified approximately 550 records. Following duplicate removal and title and abstract screening, the remaining articles underwent full-text evaluation according to the predefined eligibility criteria, resulting in 167 studies being included in the final review. Data extracted from these studies were synthesized thematically according to the five mechanistic axes rather than by disease category, consistent with the conceptual framework presented in Figure 1 and maintained throughout the subsequent sections.

CIRCADIAN CLOCK

The SCN, a small paired structure located within the hypothalamus, serves as the primary circadian pacemaker in mammals [9,10]. Light is the principal environmental cue responsible for synchronizing this master clock with the external day–night cycle, and even relatively low levels of evening light exposure can significantly suppress melatonin secretion [10,11]. The SCN transmits temporal signals to a network of peripheral clocks distributed throughout nearly all tissues, thereby maintaining synchronization between central and peripheral oscillators under normal physiological conditions. This synchrony is disrupted when the light–dark cycle changes abruptly, as occurs during rapid travel across multiple time zones, resulting in the condition commonly known as jet lag. Although the central pacemaker generally adapts within 1 or 2 days, peripheral tissue clocks require several additional days to resynchronize, with the rate of adaptation depending on both the magnitude of the phase shift and the age of the individual. Chronic night-shift work produces a similar state of circadian desynchronization, as feeding and activity patterns become misaligned with the timing signals generated by the SCN [12].

Two hormones transmit much of the circadian timing information from the SCN to peripheral tissues. Melatonin secretion increases after the onset of darkness and remains elevated throughout the night, thereby promoting and maintaining sleep. In contrast, cortisol follows an opposing rhythm, gradually rising during the latter part of the sleep period and reaching its peak between approximately 07:00 and 08:00. This early morning increase prepares the body for the metabolic demands of wakefulness rather than sleep, with its gradual nocturnal rise anticipating the transition to daytime activity [13]. Together, these hormones exemplify a broader principle whereby the SCN generates approximately 24-hour oscillations in numerous behavioral, physiological, and biochemical processes. These include cortisol secretion through regulation of the hypothalamic–pituitary–adrenal (HPA) axis and the nocturnal release of melatonin through direct SCN control [14]. Peripheral clocks remain synchronized with the central pacemaker partly through rhythmic fluctuations in core body temperature and glucocorticoid secretion, both of which serve as systemic timing signals that coordinate cellular rhythms across tissues. In addition to reflecting SCN activity, melatonin also feeds back to fine-tune the circadian system, thereby contributing to the maintenance of circadian periodicity [15].

Underlying these physiological rhythms is a highly conserved molecular network of clock genes organized into interconnected transcriptional–translational feedback loops that generate self-sustained oscillations with a period of approximately 24 hours, even in the absence of external environmental cues. CLOCK and BMAL1 constitute the positive limb of this molecular oscillator by activating transcription of the Period (PER1, PER2, and PER3) and Cryptochrome (CRY1 and CRY2) genes. As PER and CRY proteins accumulate, they inhibit the activity of CLOCK–BMAL1, thereby suppressing their own transcription. Subsequent degradation of these proteins resets the cycle and initiates the next oscillation [16]. Beyond its role in maintaining circadian timing, this molecular clock regulates diverse cellular processes, including metabolism, proliferation, and programmed cell death across mammalian tissues, providing the mechanistic basis through which circadian rhythms influence physiological processes as diverse as tumor development and cartilage homeostasis.

MECHANISTIC BASIS OF THE CIRCADIAN CROSSWALK

Inflammatory and immune dysregulation

Circadian clocks regulate both innate and adaptive immunity through the temporal control of immune cell trafficking, cytokine secretion, and inflammatory signaling. Core clock proteins, including BMAL1, CLOCK, PER, and CRY, are expressed across multiple immune cell lineages and directly regulate the transcription of immune-related genes, thereby generating daily oscillations in immune function [17,18].

Pro-inflammatory cytokines, including IL-6, TNF-α, and IL-1β, exhibit robust circadian oscillations, typically reaching peak concentrations during specific phases of the sleep–wake cycle to coordinate immune defense with the body’s behavioral and metabolic state [19,20]. Circadian disruption, whether caused by sleep deprivation, shift work, or intrinsic dysfunction of the molecular clock, abolishes this temporal regulation, resulting in persistent low-grade inflammation and aberrant immune activation [12]. At the cellular level, leukocyte trafficking between the circulation and peripheral tissues follows circadian patterns driven by the rhythmic expression of adhesion molecules and chemokines, thereby coordinating immune surveillance with anticipated physiological demands. Circadian desynchronization disrupts these processes, leading to inappropriate immune cell infiltration and prolonged inflammatory responses [21].

Macrophages provide a clear example of this regulatory mechanism. BMAL1 controls mitochondrial function and redox homeostasis in macrophages, thereby regulating activation of the NLRP3 inflammasome. Loss of BMAL1 signaling enhances inflammasome activation and increases IL-1β production [22]. Adaptive immunity is similarly regulated by the circadian clock. T-cell activation, differentiation, and cytokine secretion exhibit pronounced time-of-day variation, with circadian signaling influencing the balance between Th17 and Treg cells. Likewise, antigen presentation by dendritic cells follows a circadian rhythm [23], and disruption of this temporal regulation has been implicated in the development of autoimmune and chronic inflammatory diseases. Furthermore, sleep disturbance and inflammation reinforce one another through a reciprocal relationship, creating a self-perpetuating cycle of immune dysregulation [19].

These same mechanisms governing immune cell trafficking and cytokine regulation also determine the effectiveness of antitumor immunity. Circadian disruption reduces the activity of cytotoxic T lymphocytes and decreases the density of tumor-infiltrating lymphocytes while promoting the accumulation of immunosuppressive immune cell populations, thereby facilitating tumor immune evasion [18,24]. In mice, 21 days of chronic sleep restriction depleted effector immune cell populations both systemically and within the tumor microenvironment, while simultaneously shifting cytokine production away from the Th1 response that is most effective against malignant cells [25]. Similarly, in an animal model of hepatocellular carcinoma, sleep deprivation redistributed CD3+ T cells, NK cells, and CD11b+ myeloid cells from the tumor microenvironment to peripheral compartments, thereby accelerating tumor growth and invasion [26]. Whether comparable immune redistribution occurs in humans, and the extent of circadian disruption required to produce such effects, remains to be determined.

Metabolic disruption

Circadian clocks impose temporal organization on glucose and lipid metabolism at multiple levels, ranging from whole-body insulin sensitivity to substrate utilization within individual mitochondria. Shift work, sleep deprivation, and intrinsic dysfunction of the molecular clock ultimately converge on a common consequence: disruption of this temporal organization, leading to insulin resistance, impaired glucose homeostasis, and mitochondrial dysfunction [27,28].

Insulin sensitivity itself follows a circadian rhythm, reaching its peak during the active phase and declining during the rest phase under the coordinated regulation of central and peripheral clocks, which synchronize insulin secretion, hepatic glucose production, and peripheral glucose uptake. Circadian misalignment disrupts this coordination, resulting in reduced insulin sensitivity and elevated postprandial glucose concentrations [29,30]. BMAL1 and CLOCK directly regulate this pathway by controlling the transcription of genes involved in glucose transport, insulin receptor signaling, and broader aspects of lipid and carbohydrate metabolism. Disruption of BMAL1 decreases the phosphorylation of insulin receptor substrate-1 and AKT, thereby inducing systemic insulin resistance in experimental models [30,31]. Evidence from controlled human studies further supports a causal relationship, demonstrating that simulated shift-work protocols reduce insulin sensitivity and glucose tolerance within only a few days, independent of caloric intake or physical activity [32].

A complementary hepatic circadian clock regulates gluconeogenesis and glycogen storage through the rhythmic expression of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase [32]. Disruption of this hepatic clock promotes inappropriate nocturnal glucose production, an effect that is further exacerbated when irregular meal timing—an important zeitgeber for peripheral tissues—uncouples hepatic and pancreatic clocks from central circadian regulation [33]. Consequently, meal timing has emerged as a potential therapeutic target. Time-restricted eating (TRE), particularly when food intake is confined to the early active phase, improves insulin sensitivity and glycemic control without requiring caloric restriction [34]. Circadian fluctuations in gut microbiota composition have also been proposed as an additional mechanism linking circadian rhythms to metabolic regulation, although the strength of this association remains to be fully established.

Mitochondrial bioenergetics constitute a third major component of this mechanistic axis. Oxidative phosphorylation, fatty acid oxidation, and ATP production all exhibit circadian oscillations regulated through clock-controlled transcriptional programs. These processes are coordinated in part by the mitochondrial biogenesis regulator PGC-1α, while circadian regulation of mitochondrial fission and fusion is essential for maintaining mitochondrial integrity. Disruption of these mechanisms reduces mitochondrial efficiency, alters substrate utilization, and diminishes cellular energy production [35-37]. In skeletal muscle and liver, the resulting redox imbalance further impairs metabolic flexibility and insulin signaling, thereby amplifying the transcriptional defects described above [30].

These same metabolic pathways are frequently exploited by tumor cells. Silencing the tumor-suppressor clock gene PER2 in oral squamous cell carcinoma enhances glycolytic flux through activation of the PI3K/AKT signaling pathway, resulting in increased glucose utilization, elevated lactate production, and accelerated in vivo tumor growth [38]. Fatty acid oxidation represents another mechanism through which circadian disruption promotes tumor progression. Sleep deprivation upregulates ACSL1, leading to the accumulation of palmitoyl-CoA, which drives ZDHHC5-mediated S-palmitoylation of CLOCK, thereby stabilizing the protein in a feed-forward regulatory loop that promotes cancer stemness in lung tumor models. Timed administration of β-endorphin resynchronizes the CLOCK–ACSL1 axis and attenuates sleep deprivation-induced tumor growth. Consistent with these findings, analyses of human tumor specimens have demonstrated an inverse correlation between sleep quality and CLOCK/ACSL1 expression [39]. Time-restricted feeding may also exploit this metabolic vulnerability therapeutically. In lung cancer models, restricting feeding to a 6-hour window downregulates the clock gene TIMELESS, activates autophagy, and suppresses tumor growth, with even greater antitumor effects observed when combined with direct pharmacological inhibition of TIMELESS [40]. However, these mechanistic observations are derived primarily from cell culture and animal studies. Human evidence remains largely correlative, and whether these metabolic vulnerabilities can be effectively targeted in patients has yet to be determined through prospective clinical trials.

Oxidative stress and cellular damage

Intracellular redox balance is a dynamic process that fluctuates throughout the day under the regulation of the circadian system. Circadian rhythms coordinate antioxidant defenses, mitochondrial function, DNA repair, and cellular stress-response pathways to ensure that the production of reactive oxygen species (ROS) remains balanced with the metabolic demands of the cell [41]. BMAL1 and CLOCK contribute directly to this regulation by controlling the rhythmic expression of antioxidant enzymes, including superoxide dismutase, catalase, glutathione peroxidase, and heme oxygenase-1 [42]. In parallel, reverse erythroblastosis virus (REV-ERB) α and retinoic acid receptor-related orphan receptor (ROR) provide an additional layer of transcriptional regulation by modulating genes involved in mitochondrial respiration and lipid oxidation [43,44]. Loss of BMAL1 disrupts these antioxidant defense mechanisms, leading to intracellular ROS accumulation, increased oxidative damage, and the development of phenotypes resembling premature aging in experimental models [45]. These findings highlight the central role of an intact circadian clock in maintaining redox homeostasis beyond the intrinsic capacity of antioxidant systems alone [46,47].

Mitochondria are the principal source of intracellular ROS, and their structural and functional integrity is itself regulated by the circadian clock. Oxidative phosphorylation and electron transport chain activity exhibit robust circadian oscillations that minimize electron leakage during periods of elevated metabolic demand. Disruption of these rhythms impairs mitochondrial dynamics and reduces respiratory efficiency [48]. A related regulatory pathway involves NAD+ and SIRT1 signaling, which govern mitochondrial quality control and genomic stability. Circadian disruption alters this signaling network, and the resulting dysregulation has been associated with metabolic disorders, neurodegeneration, and age-related tissue dysfunction [46,49].

One of the strongest lines of evidence supporting the protective role of circadian regulation comes from DNA repair mechanisms [50]. Nucleotide excision repair, base excision repair, and double-strand break repair all exhibit circadian oscillations, with clock proteins regulating both the expression and activity of key DNA repair enzymes [47,51,52]. Xeroderma pigmentosum group A, the rate-limiting factor in nucleotide excision repair, is directly regulated by the CLOCK–BMAL1 complex, allowing maximal repair activity to coincide with periods of greatest genotoxic exposure [51,53]. Similarly, ATM/ATR-mediated DNA damage sensing and subsequent activation of the CHK1/CHK2 checkpoint pathways also follow circadian rhythms. Consequently, disruption of circadian timing simultaneously impairs multiple DNA repair systems, resulting in the accumulation of unrepaired DNA lesions [44,51,53,54]. Cell-cycle progression is regulated through the same circadian network. Cyclins, cyclin-dependent kinases, and checkpoint regulators, including WEE1, p21, c-Myc, and p53, are all subject to circadian transcriptional regulation, ensuring that DNA replication and mitosis remain synchronized with DNA repair capacity [5,55,56]. Loss of this synchronization increases replication stress and weakens genomic surveillance. Because tumor cells already experience greater metabolic and proliferative stress than normal cells, they appear to depend even more heavily on circadian regulation of these checkpoints. This difference constitutes one of the principal mechanistic rationales supporting the development of chronotherapy in oncology, although current evidence remains predominantly preclinical rather than clinically validated [5,54]. Supporting this concept, studies in Kras-driven lung cancer models have demonstrated that chronic circadian disruption enhances heat shock factor 1-mediated stress signaling, enabling tumor cells to adapt more effectively to oxidative and metabolic stress and thereby increasing tumor burden under otherwise unfavorable conditions [57].

Persistent oxidative stress and unresolved DNA damage ultimately drive cells into senescence through accelerated telomere shortening, impaired autophagic clearance, and direct ROS-mediated DNA injury [58,59]. Cellular senescence is accompanied by the development of the senescence-associated secretory phenotype (SASP), characterized by the secretion of pro-inflammatory cytokines, chemokines, and matrix-degrading enzymes that sustain tissue inflammation long after the initial injury has resolved [60]. Age-related decline in SIRT1-dependent DNA repair further exacerbates this inflammatory state through the same NAD+/SIRT1 signaling axis described above [46,49]. Importantly, these processes do not occur independently. ROS accumulation promotes DNA damage, impaired DNA repair accelerates genomic instability, and senescent cells further amplify oxidative and inflammatory stress through SASP, creating a self-reinforcing cycle that appears to be accelerated by circadian disruption at multiple levels [60,61].

Neuroendocrine and hormonal imbalance

The neuroendocrine system represents one of the principal pathways through which circadian regulation extends beyond the central nervous system. Through its interactions with the HPA axis, hypothalamic–pituitary–gonadal axis, hypothalamic–pituitary–thyroid axis, and the pineal melatonin system, the SCN coordinates the daily rhythms of stress hormone secretion, reproductive function, thyroid activity, and sleep regulation [62-64]. When circadian timing becomes disrupted, the resulting physiological disturbances rarely remain confined to a single endocrine axis. Instead, dysregulation of cortisol secretion, reproductive and thyroid hormone signaling, together with secondary alterations in metabolism, immune function, and mood, commonly occur simultaneously, many of which are reflected in the disease-specific conditions discussed later in this review.

Cortisol is the best-characterized endocrine output of the circadian system. Under normal physiological conditions, cortisol secretion rises before awakening and gradually declines throughout the day, preparing the body for the metabolic and cognitive demands of wakefulness. This rhythmic secretion depends on SCN-mediated regulation of hypothalamic corticotropin-releasing hormone release and subsequent adrenocorticotropic hormone secretion [63]. Chronic sleep deprivation, shift work, and irregular light exposure blunt this rhythm by reducing its amplitude and prolonging HPA axis activation rather than allowing normal circadian resetting [63,65]. For example, junior physicians monitored over 1 year of shift work developed altered diurnal cortisol rhythms characterized by increased overall cortisol secretion [66]. Likewise, controlled experimental studies have shown that a single night of total sleep deprivation increases evening cortisol concentrations by approximately 37%–45% while simultaneously attenuating normal circadian variation during the following day [67]. Sustained activation of this nature has consequences that extend beyond the immediate stress response. Chronic glucocorticoid excess promotes central adiposity, endothelial dysfunction, and persistent low-grade systemic inflammation and has been independently associated with mood disorders, cognitive impairment, and neurodegenerative diseases [65,68].

Melatonin serves as the principal hormonal effector of the circadian system. It is secreted by the pineal gland during the night under direct SCN regulation via the retinohypothalamic pathway. Exposure to artificial light at night suppresses melatonin synthesis through inhibition of arylalkylamine N-acetyltransferase [69]. Because melatonin possesses antioxidant, immunomodulatory, and mitochondrial protective properties that extend beyond its role as a circadian timing signal, suppression of its secretion has consequences beyond sleep disruption. Reduced melatonin production has been associated with metabolic dysregulation, altered cytokine profiles, and diminished antioxidant defense capacity [69,70]. Within the central nervous system, melatonin deficiency appears to exacerbate oxidative neuronal injury while promoting the accumulation of amyloid-β and hyperphosphorylated tau, the two pathological hallmarks most closely associated with Alzheimer’s disease [71-73]. In addition, melatonin regulates metabolism through activation of melatonin receptor (MT)1 and MT2 receptors expressed on pancreatic β-cells, thereby influencing insulin secretion and synchronizing peripheral metabolic clocks [73].

Melatonin has also formed the basis of one of the earliest hypotheses in circadian oncology, proposing that nocturnal light exposure suppresses melatonin production, leaves estrogen signaling relatively unopposed, and consequently increases the risk of breast cancer [74]. Although biologically plausible, the supporting evidence remains inconsistent. In murine models, repeated alterations of the light–dark cycle suppressed expression of the tumor suppressor gene Per2 while simultaneously altering Pai-1 expression, providing a potential mechanism through which circadian disruption could accelerate mammary tumor development [75]. Epidemiological studies have similarly reported that women engaged in night-shift work experience a 50%–100% higher risk of breast cancer than women working conventional daytime schedules [76]. Furthermore, prolonged sleep duration of 9 hours or more has been associated with increased breast cancer incidence among survivor cohorts [77]. Nevertheless, findings from human epidemiological studies remain inconsistent. A prospective cohort study involving more than 105,000 women in the United Kingdom reported no association between self-reported bedroom light exposure and subsequent breast cancer risk. In contrast, satellite-based assessments of nighttime light exposure conducted in Israel, South Korea, and other countries have generally demonstrated a 30%–70% increase in breast cancer risk with greater light exposure, whereas case-control studies relying on self-reported light exposure have typically produced smaller and statistically nonsignificant associations [78]. Similarly, although earlier analyses from the Nurses’ Health Study suggested an increased breast cancer risk among rotating night-shift workers [79,80], subsequent analyses after 24 years of follow-up failed to confirm this association [81]. Collectively, these findings suggest that although the proposed biological mechanism is well supported by experimental studies, it has not yet become a reliable predictor of breast cancer risk in human populations.

Appetite regulation demonstrates a similar dependence on circadian timing. Leptin concentrations normally increase during the night to promote satiety, whereas ghrelin follows a preprandial rhythm that stimulates meal initiation. Sleep deprivation and circadian misalignment reduce leptin secretion while increasing ghrelin concentrations, thereby enhancing appetite, increasing caloric intake, and promoting preference for energy-dense foods [82,83]. These changes contribute directly to obesity-related metabolic dysfunction.

Reproductive and thyroid endocrine systems likewise exhibit pronounced circadian rhythmicity. SCN-mediated pulsatile secretion of gonadotropin-releasing hormone regulates the release of luteinizing hormone and follicle-stimulating hormone [84]. Testosterone concentrations normally peak during the morning and gradually decline throughout the day, whereas circadian disruption has been associated with altered gonadotropin pulsatility, menstrual irregularities, and reduced fertility [85]. Thyroid-stimulating hormone also follows a distinct nocturnal rhythm, rising approximately 30%–50% above baseline between 23:00 and 04:00. Loss of this rhythm is associated with altered thyroid hormone secretion, impaired thermogenesis, and reduced metabolic efficiency [86].

An additional consequence of circadian disruption involves behavioral and neuropsychiatric function. Dysfunction of the molecular clock impairs functional connectivity between the prefrontal cortex and limbic structures, thereby disrupting emotional regulation and executive function [87]. Furthermore, the dopaminergic, serotonergic, and orexinergic neurotransmitter systems, all of which are regulated by circadian mechanisms, lose their normal temporal coordination under conditions of circadian disruption. These alterations have been associated with depression, anxiety disorders, and bipolar disorder [88]. Whether circadian dysfunction represents a primary cause of these psychiatric disorders or merely one contributing factor remains uncertain, as the strongest available human evidence remains largely observational rather than causal. Several therapeutic strategies specifically target these neuroendocrine pathways, including morning bright light therapy for mood disorders [89], melatonin administration for circadian phase adjustment [90], and early time-restricted feeding for metabolic realignment [91]. Therefore, the clinical evidence supporting these interventions is not discussed further in this section.

Circadian regulation of tumor biology

Core circadian clock components, including BMAL1, CLOCK, PER, CRY, REV-ERB, and ROR, interact directly with the signaling pathways that regulate tumor initiation and progression. Disruption of this molecular network generally shifts the balance toward tumor growth by altering cellular metabolism, genomic stability, and programmed cell death [5,92]. Among these components, PER2 exemplifies the dual role of circadian genes in cancer biology. In oral squamous cell carcinoma, silencing PER2 enhances cellular proliferation, suppresses apoptosis, and activates the PI3K/AKT signaling pathway, whereas restoration of PER2 expression reverses these effects, thereby inhibiting tumor growth both in vitro and in xenograft mouse models [38]. In a separate study of the same malignancy, aberrant intracellular localization of PER2, rather than simply reduced expression, impaired TP53-mediated tumor suppression and promoted epithelial–mesenchymal transition (EMT), thereby increasing the invasive potential of cancer cells [93].

The tumor-suppressive role of PER2 extends beyond oral squamous cell carcinoma and reflects a broader pattern observed across the circadian gene network, although the functions of individual clock genes vary among different tumor types. In cervical cancer, PER2 expression is significantly reduced, and restoration of its expression suppresses tumor growth in a dose-dependent manner. Similarly, breast tumors exhibiting reduced expression of CRY2, PER2, and PER3 are generally associated with more aggressive pathological characteristics and poorer clinical outcomes, frequently accompanied by disruption of the normal oscillatory coordination among these genes. In contrast, TIMELESS exhibits the opposite pattern. Rather than being downregulated, it is frequently overexpressed in malignant tissues and is associated with poor prognosis. Epigenetic silencing of circadian genes commonly results from hypermethylation of their promoter regions, a process that can be reversed using DNA methylation inhibitors. In addition, inherited genetic variation contributes to cancer susceptibility, with polymorphisms in CLOCK, CRY2, and RoRA each being associated with an increased risk of malignancy [94].

Several circadian-associated genes also promote metastatic progression through tumor-specific mechanisms. Hepatic leukemia factor (HLF), a transcription factor exhibiting circadian oscillation, is downregulated in non-small cell lung cancer. Loss of HLF removes an important inhibitory influence on NF-κB signaling mediated through PPARα and PPARγ, thereby promoting anaerobic metabolism that enables tumor cells to survive within nutrient-deprived microenvironments and facilitates metastasis to the bone, liver, and brain [95]. In estrogen receptor-negative breast cancer, inherited variants near ARNTL2 have been associated with metastatic progression [96]. Similarly, in colorectal cancer, elevated expression of human CLOCK gene correlates with lymph node metastasis, advanced disease stage, and poor prognosis, whereas experimental suppression of human CLOCK gene inhibits both EMT and metastatic behavior in preclinical models [97]. Collectively, these observations reflect a broader phenomenon whereby circadian disruption promotes cancer stem cell maintenance and tumor invasion through signaling pathways including Wnt/β-catenin, TGF-β, and NF-κB [54,98-100].

Circadian regulation also influences the tumor microenvironment by coordinating the temporal activity of immune and stromal cells surrounding developing tumors [5,101]. Importantly, this interaction is bidirectional. Tumors are not passive recipients of host circadian signals but actively secrete factors capable of reprogramming peripheral clocks in distant healthy tissues. In mouse models of lung and breast cancer, tumor-derived mediators altered hepatic lipid metabolism and oxidative stress responses in the liver, despite the absence of direct tumor involvement. The extent to which similar systemic circadian reprogramming occurs in other malignancies remains unknown. One mechanistic example has been identified in lung adenocarcinoma, where BMAL2-dependent signaling promotes metastatic progression by regulating the secretion of SMOC2, WNT5A, and CCL7, which subsequently influence the surrounding microenvironment [92].

The strongest experimental evidence demonstrating that circadian disruption alone can promote tumorigenesis comes from a mouse model of chronic jet lag. In this model, repeated advancement of the light–dark cycle by 6 hours twice daily significantly shortened tumor latency and accelerated tumor growth. Similar effects were observed in mice carrying mutations in core clock genes or following surgical ablation of the SCN, indicating that the increased tumor burden resulted from loss of circadian integrity rather than from stress associated with altered light exposure [102]. Human epidemiological studies have broadly associated shift work with an increased risk of several malignancies, including breast, prostate, and colorectal cancers [103]. However, findings become considerably less consistent when individual studies are examined in detail. A meta-analysis involving approximately 3.6 million participants reported a positive association between shift work and melanoma risk but identified a significant inverse association with basal cell carcinoma, arguing against a universal relationship between circadian disruption and skin cancer risk [104]. Likewise, a larger meta-analysis of 57 observational studies found no overall association between night-shift work and the risk of breast, prostate, ovarian, pancreatic, colorectal, gastric, or non-Hodgkin lymphoma, with an increased risk observed only among men [105]. Another meta-analysis linked night-shift work in men to lung, prostate, colon, bladder, rectal, and pancreatic cancers; however, the absence of a dose-response relationship suggested that these findings were more likely attributable to methodological bias than to a genuine causal association [106]. Genetic evidence provides somewhat stronger support for a causal role of circadian biology. A hereditary morning chronotype has been associated with a reduced risk of gastric and colorectal cancers independent of sleep duration, insomnia, and body mass index, thereby minimizing confounding by shift work [107]. Furthermore, Mendelian randomization analyses have demonstrated a causal relationship between insomnia and lung adenocarcinoma, while longer sleep duration appears to confer protection against lung cancer overall [108].

The efficacy and toxicity of anticancer therapies frequently depend on the timing of treatment administration within the circadian cycle [109]. Circadian regulation of apoptosis, autophagy, and oxidative stress influences tumor sensitivity to chemotherapy, radiotherapy, and immunotherapy at different times of the day [110]. Nevertheless, the translation of this biological knowledge into clinical practice remains at varying stages of development. Pharmacologically, small-molecule activators of CRY and REVERB have demonstrated the ability to suppress tumor progression in experimental models, although these agents have not yet been evaluated in patient-derived systems [111,112]. PER1 illustrates the complexity of circadian regulation in cancer therapy. This gene participates in DNA damage signaling through the ATM and CHK2 pathways, and alterations in its expression modify tumor cell responses to ionizing radiation. However, these effects vary among tumor types, with PER1 exhibiting both protective and detrimental influences depending on the experimental model, a phenomenon similarly observed with responses to heat shock protein 90 inhibitors [113,114]. Although the behavior of individual clock genes differs across malignancies, the broader principle remains consistent. Circadian regulators, including PER2, CRY2, and NR1D2, control the temporal expression of oncogenes and tumor suppressor genes, thereby influencing tumor sensitivity to chemotherapeutic agents such as 5-fluorouracil and docetaxel. Moreover, certain clock genes, including ARNTL2 and NR1D1, exhibit oncogenic properties, whereas members of the PER and CRY gene families generally function as tumor suppressors [115]. Clinical evidence supporting circadian-based treatment scheduling remains limited and largely preliminary. A meta-analysis of seven randomized clinical trials involving patients with advanced colorectal cancer demonstrated that chronomodulated chemotherapy did not improve objective response rates but significantly reduced hematological toxicity without increasing other adverse events [116]. Similarly, a retrospective cohort study of 121 patients with advanced melanoma found that patients receiving all of their first four immune checkpoint inhibitor infusions during the afternoon experienced shorter survival than those receiving at least one infusion in the morning. Although the magnitude of this association warrants further investigation, the findings originate from a single retrospective cohort and require confirmation in prospective clinical trials before they can inform routine clinical practice [117].

CHRONIC DISEASES AND CIRCADIAN RHYTHM

Circadian disruption rarely affects a single organ system in isolation, and few of the five mechanistic axes described above operate independently within any individual disease. Rather than providing comprehensive reviews of specific diseases, the following sections present five representative examples, each illustrating a distinct combination of circadian mechanisms manifesting in a recognizable clinical context. Cardiovascular disease and asthma primarily reflect inflammatory and neuroendocrine dysregulation, whereas osteoarthritis and Alzheimer’s disease are driven predominantly by oxidative stress and genomic instability. Type 2 diabetes occupies the intersection of the metabolic and neuroendocrine axes. Importantly, the relationship is bidirectional in each of these conditions: circadian disruption contributes to disease initiation and progression, while the disease itself further impairs sleep quality and circadian regulation, thereby reinforcing the underlying pathological process [118].

Cardiovascular disease

Cardiovascular disease offers one of the clearest illustrations of circadian regulation acting on a single organ system. In mice, deletion of the clock gene Per2 abolishes the cardioprotective effect of ischemic preconditioning through disruption of hypoxia-inducible factor 1α signaling, while timed light exposure that increases Per2 expression enhances glycolytic adaptation during ischemia and reduces infarct size [119].

Human data support this link from the vascular side. Rotating night-shift hospital workers, screened to exclude pre-existing cardiovascular risk factors, show greater carotid intima-media thickness than daytime workers, and this thickening persists after night-shift work has stopped [120]. Permanent night-shift workers also show elevated circulating IL-6 and C-reactive protein compared with daytime workers [121,122], and experimentally induced circadian misalignment raises 24-hour blood pressure in healthy volunteers without any change in diet or activity [123]. The Multi-Ethnic Study of Atherosclerosis extends these findings to a large community-based population, linking irregular sleep timing to subclinical atherosclerosis independent of the mechanistic and small clinical studies above [124].

These findings anchor cardiovascular disease within the inflammatory and neuroendocrine axes of the proposed crosswalk. The same cytokine and cortisol pathways that damage the vasculature also shape antitumor immune surveillance, linking a common chronic disease to impaired cancer immunity through a shared circadian mechanism.

Osteoarthritis

Osteoarthritis provides genomic evidence for the oxidative and genomic axis of the crosswalk. An unbiased gene set analysis of aging knee cartilage identified circadian rhythm signaling as one of the most dysregulated pathways in the tissue, without the study having been designed to test this hypothesis [125]. Cartilage-specific deletion of Bmal1 in mice accelerates cartilage degeneration through unchecked activation of mTORC1 signaling [126], and Cryptochrome 2 expression falls in osteoarthritic cartilage in both mice and humans (denoted CRY2 in human and Cry2 in mouse nomenclature), with loss of its normal circadian oscillation in affected chondrocytes [127,128]. Downstream, increased Per1 expression promotes GSK3β phosphorylation and nuclear translocation of β-catenin, raising expression of the cartilage-degrading enzymes MMP13, ADAMTS4, and ADAMTS5 [129]. Because NR1D1 and BMAL1 decline with age before cartilage damage becomes visible, attenuation of clock amplitude appears to precede rather than follow joint degeneration [130,131].

Osteoarthritis illustrates how loss of circadian gating over DNA repair and cell-cycle checkpoints, the same axis implicated in genomic instability during malignant transformation, can drive tissue degeneration well before a chronic disease becomes clinically apparent.

Alzheimer’s disease

Alzheimer’s disease links circadian sleep architecture to a hallmark disease protein. Amyloid-β clearance from the brain depends on astroglia-mediated interstitial fluid flow, a glymphatic process tied to the neuronal oscillatory activity of rapid eye movement sleep [132], and neuronal release of amyloid-β itself rises during wakefulness and falls during sleep [133,134]. Consistent with this link, individuals with post-traumatic stress disorder, a condition marked by chronic sleep disruption, carry an increased lifetime risk of the disease [135].

Circadian regulation also extends to the blood-brain barrier, where the receptor for advanced glycation end products mediates amyloid-β transport into cerebral vessels within the same regulatory network [136]. In APP/PS1 mice, clock gene expression becomes dysregulated in the cortex and hippocampus as early as 6 months of age, well before overt neurodegeneration appears at 12 months, alongside reduced hypothalamic GABAergic signaling that may explain why circadian disruption becomes harder to reverse once disease has progressed [137].

Alzheimer’s disease thus exemplifies the oxidative and genomic axis acting through a distinct route, sleep-dependent proteostasis rather than DNA repair, and shows that a single mechanistic axis can produce different disease phenotypes depending on the tissue involved.

Diabetes mellitus

Type 2 diabetes offers the clearest human evidence for the metabolic axis because sleep and meal timing can both be manipulated experimentally. A single night of total sleep loss reduces insulin sensitivity in healthy volunteers without any change in cortisol [138], and 1 week of sleep restricted to 5 hours per night lowers peripheral insulin sensitivity while sparing hepatic responsiveness, shifting substrate use toward fatty acid oxidation [139,140]. Combining sleep restriction with circadian misalignment produces a larger drop in insulin sensitivity than misalignment alone, indicating that the two stressors interact instead of acting in an additive fashion [141].

Pancreatic β-cells carry their own intrinsic clock. Loss of Bmal1 in these cells causes glucose intolerance, while its overexpression protects against obesity-induced metabolic dysfunction in mouse models [142]. Outside the laboratory, habitual breakfast skipping associates with insulin resistance and higher diabetes risk in observational cohorts [143], and melatonin shows a timing-dependent effect on glucose handling, improving β-cell function during fasting but impairing tolerance when present during food intake [144]. A hereditary evening chronotype predicts higher diabetes incidence over more than 7 years of follow-up, independent of shift-work history [145], though several transgenic and desynchronized feeding models have failed to reproduce these metabolic effects, a reminder that the circadian hypothesis of diabetes, while well supported, is not yet universal [30, 146-148].

Diabetes sits at the intersection of the metabolic and neuroendocrine axes in this crosswalk, since the same insulin and melatonin pathways disrupted by circadian misalignment also shape glucose availability within the tumor microenvironment.

Asthma

Nocturnal asthma was recognized as a distinct clinical pattern long before its circadian basis was understood, with symptoms, airway resistance, and exacerbations all worsening in the late night and early morning [149,150]. The lung carries its own peripheral clock, and BMAL1 within airway epithelial cells suppresses NF-κB signaling and limits the type 2 immune response responsible for allergic inflammation. Deletion of BMAL1 in these cells raises chemokine production and worsens eosinophilic and neutrophilic infiltration [151,152], while circadian oscillation of eosinophils and type 2 innate lymphoid cells drives nocturnal peaks in IL-5 and IL-13 [153].

This immune rhythm tracks an endocrine one. Cortisol reaches its lowest point at night, at the exact time when asthma symptoms peak and the airway loses its natural anti-inflammatory cover [154], and night-shift work worsens both asthma control and the response to inhaled corticosteroids [155]. Administering corticosteroids in the late afternoon or evening, rather than in the morning, improves nocturnal symptom control, a pattern that follows from the interaction between the cortisol nadir and the circadian peak in eosinophilic activity [156].

Asthma thus completes the set of chronic disease examples in this crosswalk, showing how inflammatory and neuroendocrine circadian pathways converge on a single organ system in a way that mirrors their combined action within the tumor immune microenvironment.

CHRONIC DISEASES AMENABLE TO TREATMENT THROUGH CIRCADIAN CLOCK ALIGNMENT WITHOUT PHARMACOTHERAPY

The biological mechanisms discussed above demonstrate that circadian disruption exerts widespread effects across interconnected inflammatory, metabolic, oxidative, neuroendocrine, and tumor-intrinsic pathways. The following section addresses the converse question: what physiological changes occur when circadian rhythms are intentionally restored? Rather than targeting downstream pathological consequences with pharmacological agents, these interventions seek to re-establish circadian alignment through the same environmental cues—light exposure, meal timing, and behavioral scheduling—that normally entrain the circadian clock. This approach differs fundamentally from chronotherapy, which focuses on optimizing the timing of existing cancer treatments according to endogenous circadian rhythms. Instead, the interventions discussed here are designed to restore the circadian system itself [157].

Light exposure provides the most direct means of resynchronizing the circadian clock, as demonstrated by delayed sleep–wake phase disorder. Adolescents and young adults with this condition who received appropriately timed morning bright light therapy experienced earlier sleep onset, shorter sleep latency, and improved daytime functioning compared with individuals receiving standard care. These findings have been sufficiently robust that the American Academy of Sleep Medicine now recommends scheduled light exposure, together with behavioral interventions, as essential components of treatment for intrinsic circadian rhythm sleep–wake disorders [158,159]. Melatonin provides a complementary physiological approach to circadian realignment. When administered in the early evening rather than as a hypnotic agent, melatonin functions primarily as a circadian timing signal that advances the phase of the biological clock. Consequently, it is used either alone or in combination with light therapy for the treatment of circadian rhythm disorders [90]. Although melatonin is administered exogenously, its role in this context is to restore circadian timing rather than to treat downstream symptoms. It is therefore considered a circadian realignment strategy rather than conventional pharmacotherapy.

The same principle extends beyond sleep regulation to mood disorders. Multiple meta-analyses have demonstrated that appropriately timed morning bright light therapy is more effective than sham light exposure for reducing depressive symptoms in seasonal affective disorder, with similar benefits observed in nonseasonal depression when treatment is administered at the appropriate circadian phase [89,160,161]. Observational evidence supports these findings. Analysis of 91,105 participants from the UK Biobank demonstrated that reduced regularity of circadian rhythms was associated with more severe depressive symptoms and poorer self-reported well-being. However, because these data are cross-sectional, they establish only an association rather than the causal relationship demonstrated by randomized light therapy trials [162]. Similar principles apply to Alzheimer’s disease. In residents of long-term care facilities, lighting systems designed to mimic natural day–night light cycles significantly improved sleep efficiency while reducing depressive symptoms and agitation without altering medication use, suggesting that circadian disturbances remain at least partially reversible even after dementia has become clinically established [163].

Meal timing represents another important avenue for circadian realignment. Three clinical trials collectively provide consistent evidence supporting this approach. Restricting food intake to a 10-hour daytime window significantly reduced blood pressure, body weight, and atherogenic lipid profiles in adults with metabolic syndrome without requiring caloric restriction [164]. Likewise, limiting food intake to a 6-hour daytime window improved insulin sensitivity, β-cell function, and blood pressure in men with prediabetes, despite no changes in total caloric intake or body weight [91]. In contrast, application of an 8-hour feeding window in adults who were overweight or obese but did not have metabolic syndrome or prediabetes produced only modest weight loss and no significant metabolic benefit compared with unrestricted daytime eating [165]. Considered together, these studies suggest that the cardiometabolic benefits of TRE may depend on the presence of underlying metabolic dysfunction. The intervention appears consistently effective in metabolic syndrome and prediabetes but has not yet been established as an effective stand-alone treatment for obesity alone.

Cognitive behavioral therapy for insomnia (CBT-I) operates through a broader range of mechanisms than the interventions described above, although part of its therapeutic effect likely results from circadian realignment. In addition to addressing maladaptive cognitive and behavioral factors associated with insomnia, CBT-I promotes a consistent sleep–wake schedule, thereby functioning as a behavioral zeitgeber that reinforces circadian synchronization. A systematic review and meta-analysis of randomized controlled trials demonstrated that CBT-I significantly reduced sleep latency and wakefulness after sleep onset while improving sleep efficiency, with these benefits persisting during follow-up [166]. The extent to which these improvements result specifically from restoration of circadian timing, as opposed to the cognitive components of therapy, remains uncertain. Most likely, both mechanisms contribute to the overall therapeutic effect.

DISCUSSION

The evidence synthesized here supports five interconnected mechanistic axes rather than five independent disease-specific pathways. Inflammatory signaling, metabolic regulation, oxidative stress and genome maintenance, neuroendocrine function, and tumor-intrinsic circadian mechanisms should not be viewed as separate processes that happen to share a circadian component. They constitute an integrated biological network, and the cardiovascular, osteoarthritis, Alzheimer disease, diabetes, and asthma examples each represent a distinct manifestation of dysfunction within this common system. The oxidative stress and genomic instability that drive cartilage degeneration in osteoarthritis are the same processes that allow genetically damaged cells to escape repair and undergo malignant transformation. The neuroendocrine mechanisms that flatten the normal morning cortisol surge in shift workers also govern the availability of melatonin to breast tumors at night. Chronic disease and cancer should therefore be regarded not as independent outcomes of circadian disruption but as different clinical manifestations of a common disturbance in circadian regulation. This shared mechanistic framework forms the basis of the circadian crosswalk proposed here.

The strength of evidence supporting individual components of this crosswalk varies, and these differences deserve direct acknowledgment. Circadian regulation of DNA repair rests on converging evidence from molecular biology, animal knockout models, and a growing body of human epidemiological studies, and represents one of the most robust areas of circadian research available today. Evidence on the timing of immune checkpoint inhibitor administration remains far more limited by contrast. A retrospective cohort of 121 patients showed a striking survival difference according to infusion time, but the findings come from a single center, and despite the large effect size, the result cannot be considered clinically definitive until confirmed by prospective randomized trials [117]. Chronomodulated chemotherapy sits at an intermediate point in this evidence hierarchy. It has been evaluated in seven randomized clinical trials, yet the demonstrated benefit has been reduced treatment toxicity rather than improved tumor response or survival, a distinction easily lost when the findings are summarized in brief [116]. Table 1 presents the available evidence by mechanistic axis for this reason, rather than folding studies of different quality into one uniform narrative.

Circadian mechanisms linking chronic disease and antitumor immunity

The available therapeutic evidence also falls into two complementary strategies, interventions that synchronize treatment with existing circadian rhythms, and interventions that aim to restore circadian rhythms themselves. Circadian realignment approaches, including morning light therapy timed for delayed sleep–wake phase disorder, TRE for metabolic syndrome and prediabetes, and CBT-I built around fixed sleep schedules, are all supported by randomized clinical trial evidence. Even these interventions are not effective in every case. TRE improves metabolic outcomes in people with metabolic syndrome or prediabetes, yet similar interventions have not shown meaningful benefit in uncomplicated obesity without accompanying metabolic disease. A circadian intervention with sound biological rationale cannot be assumed to help every clinical condition on this basis. Chronotherapy for cancer, by contrast, sits at a much earlier stage of development. Experimental activation of CRY and REV-ERB signaling has shown antitumor activity in laboratory models, yet these approaches have not moved beyond preclinical investigation. Several mechanistic components of circadian regulation are well established when the available evidence is taken together, whereas their clinical translation remains incomplete.

One of the main contributions of this review is to bring together fields that have developed on separate tracks. Chondrocyte circadian biology, HPA axis endocrinology, and immune checkpoint pharmacology sit in separate scientific disciplines and appear in different specialist journals as a rule. Individual pieces of this broader framework, such as the cardiometabolic consequences of circadian disruption, have already been the subject of dedicated reviews [167]. By identifying the circadian mechanisms shared across these otherwise distinct areas of research, this review offers a unified framework linking chronic disease biology with cancer immunology. The literature search, spanning nearly three decades and three major biomedical databases, was broad enough to capture both the foundational molecular discoveries of the early 2000s and the most recent clinical evidence.

Several limitations of the current evidence base deserve acknowledgment. Much of the evidence linking circadian disruption to immune evasion and tumor progression comes from animal models and small retrospective human cohorts rather than large prospective studies capable of establishing causal relationships with confidence. No widely accepted biomarker panel exists for quantifying the severity of circadian disruption. None of the human studies included here classified participants using a standardized measure of circadian dysfunction as a result, which makes comparisons across studies difficult by nature. Conditions as different as rotating shift work, chronic insomnia, and a single night of sleep deprivation are often grouped together despite the chance that they represent distinct biological forms of disruption. Finally, this work is a narrative review and not a systematic review, a choice made because much of the available literature remains mechanistic and preclinical rather than trial-based. Narrative synthesis still carries a greater risk of selection bias than systematic review methodology, and that risk should be weighed against the benefit of a broader synthesis across fields that a systematic protocol would not easily accommodate.

Several priorities should guide future research aimed at moving circadian biology into clinical practice. First, a standardized biomarker panel that combines actigraphy, clock gene expression in accessible tissues, and cortisol and melatonin profiling would let future studies classify patients by degree of circadian disruption instead of relying only on shift-work history. Second, prospective clinical trials that evaluate immunotherapy timing should be powered from the outset to assess survival outcomes rather than tolerability alone, and should be registered before patient enrollment begins. Such trials are needed to determine whether the retrospective melanoma survival association reflects a genuine biological phenomenon or an observation unique to a single cohort. Finally, chronotherapy protocols should extend beyond the narrow range of cancer types studied so far, with particular attention to malignancies in which circadian clock gene disruption is most pronounced rather than extrapolating findings from colorectal cancer to unrelated tumor types.

Notes

The authors have no potential conflicts of interest to disclose.

Availability of Data and Material

Data sharing not applicable to this article as no datasets were generated or analyzed during the study.

Author Contributions

Conceptualization: Hoda Mojiri-Forushani. Investigation: Ali Asghar Hemmati, Farab Pourhasan, Daryoush Kiani-Shamsabadi, Seyed Ali Mahfouzi Mousavi, Seyed Mohammad Salehi-Behbahani. Methodology: Farab Pourhasan, Daryoush Kiani-Shamsabadi. Supervision: Hoda Mojiri-Forushani, Elaheh Karimzadeh-Soureshjani. Writing—original draft: Farab Pourhasan, Daryoush Kiani-Shamsabadi, Seyed Ali Mahfouzi Mousavi. Writing—review & editing: Hoda Mojiri-Forushani, Elaheh Karimzadeh-Soureshjani, Ali Asghar Hemmati, Seyed Mohammad Salehi-Behbahani.

Funding Statement

This project was financially supported by Abadan University of Medical Sciences, Abadan, Iran (Grant No: U-2323).

Acknowledgments

This review was conducted in accordance with the research policy of Abadan University of Medical Sciences under ethics code IR.ABADANUMS.REC.1404.120.

References

1. Ruiz FS, Beijamini F, Beale AD, Gonçalves BDSB, Vartanian D, Taporoski TP, et al. Early chronotype with advanced activity rhythms and dim light melatonin onset in a rural population. J Pineal Res 2020;69e12675.
2. Pfeffer M, Korf HW, Wicht H. Synchronizing effects of melatonin on diurnal and circadian rhythms. Gen Comp Endocrinol 2018;258:215–221.
3. Wong SD, Wright KP Jr, Spencer RL, Vetter C, Hicks LM, Jenni OG, et al. Development of the circadian system in early life: maternal and environmental factors. J Physiol Anthropol 2022;41:22.
4. Cermakian N, Lange T, Golombek D, Sarkar D, Nakao A, Shibata S, et al. Crosstalk between the circadian clock circuitry and the immune system. Chronobiol Int 2013;30:870–888.
5. Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer 2019;5:475–494.
6. Fishbein AB, Knutson KL, Zee PC. Circadian disruption and human health. J Clin Invest 2021;131e148286.
7. Hasenmajer V, Sbardella E, Sciarra F, Simeoli C, Pivonello C, Ceccato F, et al. Circadian clock disruption impairs immune oscillation in chronic endogenous hypercortisolism: a multi-level analysis from a multicentre clinical trial. EBioMedicine 2024;110:105462.
8. Ferreira RCM, Ruiz FS, de Mello MT. Human sleep and immunity: the role of circadian patterns. Handb Clin Neurol 2025;206:93–103.
9. Reddy S, Sharma S. Physiology, circadian rhythm. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2026. Available at: https://www.ncbi.nlm.nih.gov/books/NBK519507. Accessed May 1, 2026.
10. Burke TM, Markwald RR, Chinoy ED, Snider JA, Bessman SC, Jung CM, et al. Combination of light and melatonin time cues for phase advancing the human circadian clock. Sleep 2013;36:1617–1624.
11. Hartstein LE, Diniz Behn C, Wright KP Jr, Akacem LD, Stowe SR, LeBourgeois MK. Evening light intensity and phase delay of the circadian clock in early childhood. J Biol Rhythms 2023;38:77–86.
12. Mok H, Ostendorf E, Ganninger A, Adler AJ, Hazan G, Haspel JA. Circadian immunity from bench to bedside: a practical guide. J Clin Invest 2024;134e175706.
13. Gamble KL, Berry R, Frank SJ, Young ME. Circadian clock control of endocrine factors. Nat Rev Endocrinol 2014;10:466–475.
14. Coogan AN, McGowan NM. A systematic review of circadian function, chronotype and chronotherapy in attention deficit hyperactivity disorder. Atten Defic Hyperact Disord 2017;9:129–147.
15. Komarzynski S, Bolborea M, Huang Q, Finkenstädt B, Lévi F. Predictability of individual circadian phase during daily routine for medical applications of circadian clocks. JCI Insight 2019;4e130423.
16. Luna-Marco C, Devos D, Cacace J, Fernandez-Reyes M, Díaz-Pozo P, Salazar JD, et al. Molecular circadian clock disruption in the leukocytes of individuals with type 2 diabetes and overweight, and its relationship with leukocyte-endothelial interactions. Diabetologia 2024;67:2316–2328.
17. Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. Nat Rev Immunol 2013;13:190–198.
18. Zeng Y, Guo Z, Wu M, Chen F, Chen L. Circadian rhythm regulates the function of immune cells and participates in the development of tumors. Cell Death Discov 2024;10:199.
19. Veler H. Sleep and inflammation: bidirectional relationship. Sleep Med Clin 2023;18:213–218.
20. Zielinski MR, Gibbons AJ. Neuroinflammation, sleep, and circadian rhythms. Front Cell Infect Microbiol 2022;12:853096.
21. Zeng Q, Oliva VM, Moro MÁ, Scheiermann C. Circadian effects on vascular immunopathologies. Circ Res 2024;134:791–809.
22. Pourcet B, Duez H. Circadian control of inflammasome pathways: implications for circadian medicine. Front Immunol 2020;11:1630.
23. Ince LM, Barnoud C, Lutes LK, Pick R, Wang C, Sinturel F, et al. Influence of circadian clocks on adaptive immunity and vaccination responses. Nat Commun 2023;14:476.
24. Pick R, Wang C, Zeng Q, Gül ZM, Scheiermann C. Circadian rhythms in anticancer immunity: mechanisms and treatment opportunities. Annu Rev Immunol 2024;42:83–102.
25. De Lorenzo BHP, Novaes E Brito RR, Paslar Leal T, Piqueira Garcia N, Martins Dos Santos RM, Alvares-Saraiva AM, et al. Chronic sleep restriction impairs the antitumor immune response in mice. Neuroimmunomodulation 2018;25:59–67.
26. Huang J, Song P, Hang K, Chen Z, Zhu Z, Zhang Y, et al. Sleep deprivation disturbs immune surveillance and promotes the progression of hepatocellular carcinoma. Front Immunol 2021;12:727959.
27. Poggiogalle E, Jamshed H, Peterson CM. Circadian regulation of glucose, lipid, and energy metabolism in humans. Metabolism 2018;84:11–27.
28. Rovira-Llopis S, Luna-Marco C, Perea-Galera L, Bañuls C, Morillas C, Victor VM. Circadian alignment of food intake and glycaemic control by time-restricted eating: a systematic review and meta-analysis. Rev Endocr Metab Disord 2024;25:325–337.
29. Kulkarni SS, Singh O, Zigman JM. The intersection between ghrelin, metabolism and circadian rhythms. Nat Rev Endocrinol 2024;20:228–238.
30. Stenvers DJ, Scheer FAJL, Schrauwen P, La Fleur SE, Kalsbeek A. Circadian clocks and insulin resistance. Nat Rev Endocrinol 2019;15:75–89.
31. Sulaimani N, Houghton MJ, Bonham MP, Williamson G. Effects of (poly) phenols on circadian clock gene–mediated metabolic homeostasis in cultured mammalian cells: a scoping review. Adv Nutr 2024;15:100232.
32. Speksnijder EM, Bisschop PH, Siegelaar SE, Stenvers DJ, Kalsbeek A. Circadian desynchrony and glucose metabolism. J Pineal Res 2024;76e12956.
33. Bolshette N, Ibrahim H, Reinke H, Asher G. Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology. Nat Rev Gastroenterol Hepatol 2023;20:695–707.
34. Bruno J, Walker JM, Nasserifar S, Upadhyay D, Ronning A, Vanegas SM, et al. Weight-neutral early time-restricted eating improves glycemic variation and time in range without changes in inflammatory markers. iScience 2024;27:111501.
35. Latha Laxmi IP, Job AT, Manickam V, Tamizhselvi R. Intertwined relationship of dynamin-related protein 1, mitochondrial metabolism and circadian rhythm. Mol Biol Rep 2024;51:488.
36. Aguilar-López BA, Moreno-Altamirano MMB, Dockrell HM, Duchen MR, Sánchez-García FJ. Mitochondria: an integrative hub coordinating circadian rhythms, metabolism, the microbiome, and immunity. Front Cell Dev Biol 2020;8:51.
37. Reinke H, Asher G. Crosstalk between metabolism and circadian clocks. Nat Rev Mol Cell Biol 2019;20:227–241.
38. Long W, Gong X, Yang Y, Yang K. Downregulation of PER2 promotes tumor progression by enhancing glycolysis via the phosphatidylinositol 3-kinase/protein kinase B pathway in oral squamous cell carcinoma. J Oral Maxillofac Surg 2020;78:1780.e1–1780.e14.
39. Peng F, Lu J, Su K, Liu X, Luo H, He B, et al. Oncogenic fatty acid oxidation senses circadian disruption in sleep-deficiency-enhanced tumorigenesis. Cell Metab 2024;36:1598–1618.e11.
40. Shi D, Fang G, Chen Q, Li J, Ruan X, Lian X. Six-hour time-restricted feeding inhibits lung cancer progression and reshapes circadian metabolism. BMC Med 2023;21:417.
41. Wilking M, Ndiaye M, Mukhtar H, Ahmad N. Circadian rhythm connections to oxidative stress: implications for human health. Antioxid Redox Signal 2013;19:192–208.
42. Stangherlin A, Reddy AB. Regulation of circadian clocks by redox homeostasis. J Biol Chem 2013;288:26505–26511.
43. Adlanmerini M, Lazar MA. The REV-ERB nuclear receptors: timekeepers for the core clock period and metabolism. Endocrinology 2023;164:bqad069.
44. Kettner NM, Voicu H, Finegold MJ, Coarfa C, Sreekumar A, Putluri N, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. Cancer Cell 2016;30:909–924.
45. Liang C, Ke Q, Liu Z, Ren J, Zhang W, Hu J, et al. BMAL1 moonlighting as a gatekeeper for LINE1 repression and cellular senescence in primates. Nucleic Acids Res 2022;50:3323–3347.
46. Schibler U. Senescence of timing reverted: NAD+ rejuvenates the circadian clock. Mol Cell 2020;78:805–807.
47. Im JS, Jung BH, Kim SE, Lee KH, Lee JK. Per3, a circadian gene, is required for Chk2 activation in human cells. FEBS Lett 2010;584:4731–4734.
48. Ezagouri S, Asher G. Circadian control of mitochondrial dynamics and functions. Curr Opin Physiol 2018;5:25–29.
49. Thapa R, Moglad E, Afzal M, Gupta G, Bhat AA, Hassan Almalki W, et al. The role of sirtuin 1 in ageing and neurodegenerative disease: a molecular perspective. Ageing Res Rev 2024;102:102545.
50. Li S, Zhang L. Circadian control of global transcription. Biomed Res Int 2015;2015:187809.
51. Sancar A, Lindsey-Boltz LA, Kang TH, Reardon JT, Lee JH, Ozturk N. Circadian clock control of the cellular response to DNA damage. FEBS Lett 2010;584:2618–2625.
52. Sancar A, Van Gelder RN. Clocks, cancer, and chronochemotherapy. Science 2021;371eabb0738.
53. Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proc Natl Acad Sci U S A 2009;106:2864–2867.
54. Fortin BM, Mahieu AL, Fellows RC, Kang Y, Lewis AN, Ead AS, et al. The diverse roles of the circadian clock in cancer. Nat Cancer 2025;6:753–767.
55. Shostak A. Circadian clock, cell division, and cancer: from molecules to organism. Int J Mol Sci 2017;18:873.
56. Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer 2009;9:886–896.
57. Pariollaud M, Ibrahim LH, Irizarry E, Mello RM, Chan AB, Altman BJ, et al. Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer. Sci Adv 2022;8eabo1123.
58. Hruby AJ, Higuchi-Sanabria R. Mitochondrial dysfunction in cellular senescence: a bridge to neurodegenerative disease. NPJ Aging 2025;11:99.
59. Wei ZH, Dong ZR, Li AS, Li QY, Shi J, Wang KS, et al. Circadian clock and cancer. Mil Med Res 2026;13:100025.
60. Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al. Cellular senescence: defining a path forward. Cell 2019;179:813–827.
61. Budkowska M, Cecerska-Heryć E, Marcinowska Z, Siennicka A, Dołęgowska B. The influence of circadian rhythm on the activity of oxidative stress enzymes. Int J Mol Sci 2022;23:14275.
62. Hastings MH, Maywood ES, Brancaccio M. Generation of circadian rhythms in the suprachiasmatic nucleus. Nat Rev Neurosci 2018;19:453–469.
63. Nicolaides NC, Charmandari E, Chrousos GP, Kino T. Circadian endocrine rhythms: the hypothalamic-pituitary-adrenal axis and its actions. Ann N Y Acad Sci 2014;1318:71–80.
64. Bass J, Lazar MA. Circadian time signatures of fitness and disease. Science 2016;354:994–999.
65. Baxter M, Ray DW. Circadian rhythms in innate immunity and stress responses. Immunology 2020;161:261–267.
66. Li J, Bidlingmaier M, Petru R, Pedrosa Gil F, Loerbroks A, Angerer P. Impact of shift work on the diurnal cortisol rhythm: a one-year longitudinal study in junior physicians. J Occup Med Toxicol 2018;13:23.
67. Leproult R, Copinschi G, Buxton O, Van Cauter E. Sleep loss results in an elevation of cortisol levels the next evening. Sleep 1997;20:865–870.
68. Li Y, Lu L, Androulakis IP. The physiological and pharmacological significance of the circadian timing of the HPA axis: a mathematical modeling approach. J Pharm Sci 2024;113:33–46.
69. Pfeffer M, von Gall C, Wicht H, Korf HW. The role of the melatoninergic system in circadian and seasonal rhythms—insights from different mouse strains. Front Physiol 2022;13:883637.
70. Hardeland R. Redox biology of melatonin: discriminating between circadian and noncircadian functions. Antioxid Redox Signal 2022;37:704–725.
71. Melhuish Beaupre LM, Brown GM, Gonçalves VF, Kennedy JL. Melatonin’s neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders. Transl Psychiatry 2021;11:339.
72. Lashgari NA, Tajdari M, Nikdoost P, Mavaddat H, Peyrovinasab A, Momeni Roudsari N, et al. Melatonin: novel insights in the treatment of neurodegenerative diseases. Curr Med Chem 2026;Feb. 23. [Epub]. Available at: http://doi.org/10.2174/0109298673416300251023052701.
73. Kalsbeek A, La Fleur S, Fliers E. Circadian control of glucose metabolism. Mol Metab 2014;3:372–383.
74. Stevens RG. Artificial lighting in the industrialized world: circadian disruption and breast cancer. Cancer Causes Control 2006;17:501–507.
75. Numata M, Hirano A, Yamamoto Y, Yasuda M, Miura N, Sayama K, et al. Metastasis of breast cancer promoted by circadian rhythm disruption due to light/dark shift and its prevention by dietary quercetin in mice. J Circadian Rhythms 2021;19:2.
76. Touitou Y, Reinberg A, Touitou D. Association between light at night, melatonin secretion, sleep deprivation, and the internal clock: health impacts and mechanisms of circadian disruption. Life Sci 2017;173:94–106.
77. D’cunha K, Park Y, Protani MM, Reeves MM. Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: a systematic review. Breast Cancer Res Treat 2023;198:413–421.
78. Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ. Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study. Br J Cancer 2018;118:600–606.
79. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 2001;93:1563–1568.
80. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiology 2006;17:108–111.
81. Wegrzyn LR, Tamimi RM, Rosner BA, Brown SB, Stevens RG, Eliassen AH, et al. Rotating night-shift work and the risk of breast cancer in the nurses’ health studies. Am J Epidemiol 2017;186:532–540.
82. Chaput JP, McHill AW, Cox RC, Broussard JL, Dutil C, da Costa BGG, et al. The role of insufficient sleep and circadian misalignment in obesity. Nat Rev Endocrinol 2023;19:82–97.
83. Ravi N, Gaur A, Varatharajan S, Earl EH, Kalpana M, Kamble P, et al. Sleep and chrononutrition: a narrative review. Sleep Biol Rhythms 2025;23:411–417.
84. Simonneaux V, Bahougne T. A multi-oscillatory circadian system times female reproduction. Front Endocrinol (Lausanne) 2015;6:157.
85. McHill AW, Hull JT, Klerman EB. Chronic circadian disruption and sleep restriction influence subjective hunger, appetite, and food preference. Nutrients 2022;14:1800.
86. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev 2014;94:355–382.
87. Meyer N, Lok R, Schmidt C, Kyle SD, McClung CA, Cajochen C, et al. The sleep-circadian interface: a window into mental disorders. Proc Natl Acad Sci U S A 2024;121e2214756121.
88. Hyndych A, Koval K, Dzeruzhynska N, Mader EC. Sleep and psychiatric disorders: bidirectional interactions and shared neurobiological mechanisms. PLOS Ment Health 2025;2e0000531.
89. Hirakawa H. Bright light therapy for nonseasonal depressive disorders. JAMA Psychiatry 2025;82:324.
90. Quera-Salva MA, Kilic-Huck U, Vecchierini MF. Melatonin (MEL) and its use in circadian rhythm sleep-wake disorders: recommendations of the French Medical and Research Sleep Society (SFRMS). Rev Neurol (Paris) 2021;177:235–244.
91. Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab 2018;27:1212–1221.e3.
92. Masri S, Sassone-Corsi P. The emerging link between cancer, metabolism, and circadian rhythms. Nat Med 2018;24:1795–1803.
93. Guo F, Tang Q, Chen G, Sun J, Zhu J, Jia Y, et al. Aberrant expression and subcellular localization of PER2 promote the progression of oral squamous cell carcinoma. Biomed Res Int 2020;2020:8587458.
94. Davis K, Roden LC, Leaner VD, van der Watt PJ. The tumour suppressing role of the circadian clock. IUBMB Life 2019;71:771–780.
95. Chen J, Liu A, Lin Z, Wang B, Chai X, Chen S, et al. Downregulation of the circadian rhythm regulator HLF promotes multiple-organ distant metastases in non-small cell lung cancer through PPAR/NF-κb signaling. Cancer Lett 2020;482:56–71.
96. Ha NH, Long J, Cai Q, Shu XO, Hunter KW. The circadian rhythm gene Arntl2 is a metastasis susceptibility gene for estrogen receptor-negative breast cancer. PLoS Genet 2016;12e1006267.
97. Wang Y, Sun N, Lu C, Bei Y, Qian R, Hua L. Upregulation of circadian gene ‘hClock’ contribution to metastasis of colorectal cancer. Int J Oncol 2017;50:2191–2199.
98. Relógio A, Thomas P, Medina-Pérez P, Reischl S, Bervoets S, Gloc E, et al. Ras-mediated deregulation of the circadian clock in cancer. PLoS Genet 2014;10e1004338.
99. Dierickx P, Van Laake LW, Geijsen N. Circadian clocks: from stem cells to tissue homeostasis and regeneration. EMBO Rep 2018;19:18–28.
100. Wang Y, Narasimamurthy R, Qu M, Shi N, Guo H, Xue Y, et al. Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis. Nat Cancer 2024;5:546–556.
101. Fortin BM, Pfeiffer SM, Insua-Rodríguez J, Alshetaiwi H, Moshensky A, Song WA, et al. Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade. Nat Immunol 2024;25:1257–1269.
102. Aiello I, Mul Fedele ML, Román F, Marpegan L, Caldart C, Chiesa JJ, et al. Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation. Sci Adv 2020;6eaaz4530.
103. Miro C, Docimo A, Barrea L, Verde L, Cernea S, Sojat AS, et al. “Time” for obesity-related cancer: the role of the circadian rhythm in cancer pathogenesis and treatment. Semin Cancer Biol 2023;91:99–109.
104. Yousef E, Mitwally N, Noufal N, Tahir MR. Shift work and risk of skin cancer: a systematic review and meta-analysis. Sci Rep 2020;10:2012.
105. Dun A, Zhao X, Jin X, Wei T, Gao X, Wang Y, et al. Association between night-shift work and cancer risk: updated systematic review and meta-analysis. Front Oncol 2020;10:1006.
106. Parent MÉ, El-Zein M, Rousseau MC, Pintos J, Siemiatycki J. Night work and the risk of cancer among men. Am J Epidemiol 2012;176:751–759.
107. Yuan S, Mason AM, Titova OE, Vithayathil M, Kar S, Chen J, et al. Morning chronotype and digestive tract cancers: Mendelian randomization study. Int J Cancer 2023;152:697–704.
108. Wang J, Tang H, Duan Y, Yang S, An J. Association between sleep traits and lung cancer: a Mendelian randomization study. J Immunol Res 2021;2021:1893882.
109. Ohdo S, Koyanagi S, Matsunaga N. Implications of biological clocks in pharmacology and pharmacokinetics of antitumor drugs. J Control Release 2023;364:490–507.
110. Zhou L, Zhang Z, Nice E, Huang C, Zhang W, Tang Y. Circadian rhythms and cancers: the intrinsic links and therapeutic potentials. J Hematol Oncol 2022;15:21.
111. Munteanu C, Turti S, Achim L, Muresan R, Souca M, Prifti E, et al. The relationship between circadian rhythm and cancer disease. Int J Mol Sci 2024;25:5846.
112. Yan Y, Su L, Huang S, He Q, Lu J, Luo H, et al. Circadian rhythms and breast cancer: unraveling the biological clock’s role in tumor microenvironment and ageing. Front Immunol 2024;15:1444426.
113. Bellet MM, Stincardini C, Costantini C, Gargaro M, Pieroni S, Castelli M, et al. The circadian protein PER1 modulates the cellular response to anticancer treatments. Int J Mol Sci 2021;22:2974.
114. Zhu L, Wang Q, Hu Y, Wang F. The circadian gene Per1 plays an important role in radiation-induced apoptosis and DNA damage in glioma. Asian Pac J Cancer Prev 2019;20:2195–2201.
115. Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, et al. The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst 2018;6:314–328.e2.
116. Nassar A, Abdelhamid A, Ramsay G, Bekheit M. Chronomodulated administration of chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis. Cureus 2023;15e36522.
117. Yeung C, Kartolo A, Tong J, Hopman W, Baetz T. Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma. Immunotherapy 2023;15:819–826.
118. Montaruli A, Castelli L, Mulè A, Scurati R, Esposito F, Galasso L, et al. Biological rhythm and chronotype: new perspectives in health. Biomolecules 2021;11:487.
119. Eckle T, Hartmann K, Bonney S, Reithel S, Mittelbronn M, Walker LA, et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat Med 2012;18:774–782.
120. Rizza S, Longo S, Piciucchi G, Romanello D, Mavilio M, Montagna M, et al. Carotid intimal medial thickness in rotating night shift is related to IL1β/IL6 axis. Nutr Metab Cardiovasc Dis 2020;30:1826–1832.
121. Amano H, Fukuda Y, Yokoo T, Yamaoka K. Interleukin-6 level among shift and night workers in Japan: cross-sectional analysis of the J-HOPE study. J Atheroscler Thromb 2018;25:1206–1214.
122. Kervezee L, Kosmadopoulos A, Boivin DB. Metabolic and cardiovascular consequences of shift work: the role of circadian disruption and sleep disturbances. Eur J Neurosci 2020;51:396–412.
123. Morris CJ, Purvis TE, Hu K, Scheer FA. Circadian misalignment increases cardiovascular disease risk factors in humans. Proc Natl Acad Sci U S A 2016;113:E1402–E1411.
124. Full KM, Huang T, Shah NA, Allison MA, Michos ED, Duprez DA, et al. Sleep irregularity and subclinical markers of cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2023;12e027361.
125. Li H, Yang Y, Li B, Yang J, Liu P, Gao Y, et al. Comprehensive analysis reveals the potential diagnostic value of biomarkers associated with aging and circadian rhythm in knee osteoarthritis. Orthop Surg 2025;17:922–938.
126. Qian Z, Gao X, Jin X, Kang X, Wu S. Cartilage-specific deficiency of clock gene Bmal1 accelerated articular cartilage degeneration in osteoarthritis by up-regulation of mTORC1 signaling. Int Immunopharmacol 2023;115:109692.
127. Bekki H, Duffy T, Okubo N, Olmer M, Alvarez-Garcia O, Lamia K, et al. Suppression of circadian clock protein cryptochrome 2 promotes osteoarthritis. Osteoarthritis Cartilage 2020;28:966–976.
128. Fisch KM, Gamini R, Alvarez-Garcia O, Akagi R, Saito M, Muramatsu Y, et al. Identification of transcription factors responsible for dysregulated networks in human osteoarthritis cartilage by global gene expression analysis. Osteoarthritis Cartilage 2018;26:1531–1538.
129. Wei J, Wang Y, Tu S, Zhang S, Feng Y, Hou Y, et al. Circadian rhythm disruption upregulating Per1 in mandibular condylar chondrocytes mediating temporomandibular joint osteoarthritis via GSK3β/β-CATENIN pathway. J Transl Med 2024;22:662.
130. Gossan N, Zeef L, Hensman J, Hughes A, Bateman JF, Rowley L, et al. The circadian clock in murine chondrocytes regulates genes controlling key aspects of cartilage homeostasis. Arthritis Rheum 2013;65:2334–2345.
131. Akagi R, Akatsu Y, Fisch KM, Alvarez-Garcia O, Teramura T, Muramatsu Y, et al. Dysregulated circadian rhythm pathway in human osteoarthritis: NR1D1 and BMAL1 suppression alters TGF-β signaling in chondrocytes. Osteoarthritis Cartilage 2017;25:943–951.
132. Ramanathan A, Nelson AR, Sagare AP, Zlokovic BV. Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease: the role, regulation and restoration of LRP1. Front Aging Neurosci 2015;7:136.
133. Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science 2016;354:1004–1008.
134. Shokri-Kojori E, Wang GJ, Wiers CE, Demiral SB, Guo M, Kim SW, et al. β-amyloid accumulation in the human brain after one night of sleep deprivation. Proc Natl Acad Sci U S A 2018;115:4483–4488.
135. Delic V, Ratliff WA, Citron BA. Sleep deprivation, a link between post-traumatic stress disorder and Alzheimer’s disease. J Alzheimers Dis 2021;79:1443–1449.
136. Schurhoff N, Toborek M. Circadian rhythms in the blood-brain barrier: impact on neurological disorders and stress responses. Mol Brain 2023;16:5.
137. Carrero L, Antequera D, Alcalde I, Megías D, Figueiro-Silva J, Merayo-Lloves J, et al. Disturbed circadian rhythm and retinal degeneration in a mouse model of Alzheimer’s disease. Acta Neuropathol Commun 2023;11:55.
138. González-Ortiz M, Martínez-Abundis E, Balcázar-Muñoz BR, Pascoe-González S. Effect of sleep deprivation on insulin sensitivity and cortisol concentration in healthy subjects. Diabetes Nutr Metab 2000;13:80–83.
139. Rao MN, Neylan TC, Grunfeld C, Mulligan K, Schambelan M, Schwarz JM. Subchronic sleep restriction causes tissue-specific insulin resistance. J Clin Endocrinol Metab 2015;100:1664–1671.
140. Buxton OM, Pavlova M, Reid EW, Wang W, Simonson DC, Adler GK. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes 2010;59:2126–2133.
141. Mason IC, Qian J, Adler GK, Scheer FAJL. Impact of circadian disruption on glucose metabolism: implications for type 2 diabetes. Diabetologia 2020;63:462–472.
142. Peng F, Li X, Xiao F, Zhao R, Sun Z. Circadian clock, diurnal glucose metabolic rhythm, and dawn phenomenon. Trends Neurosci 2022;45:471–482.
143. Verde L, Di Lorenzo T, Savastano S, Colao A, Barrea L, Muscogiuri G. Chrononutrition in type 2 diabetes mellitus and obesity: a narrative review. Diabetes Metab Res Rev 2024;40e3778.
144. Garaulet M, Qian J, Florez JC, Arendt J, Saxena R, Scheer FAJL. Melatonin effects on glucose metabolism: time to unlock the controversy. Trends Endocrinol Metab 2020;31:192–204.
145. Kianersi S, Liu Y, Guasch-Ferré M, Redline S, Schernhammer E, Sun Q, et al. Chronotype, unhealthy lifestyle, and diabetes risk in middle-aged U.S. women: a prospective cohort study. Ann Intern Med 2023;176:1330–1339.
146. Liu H, Wu Y, Zhu H, Wang P, Chen T, Xia A, et al. Association between napping and type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2024;15:1294638.
147. Oishi K, Atsumi G, Sugiyama S, Kodomari I, Kasamatsu M, Machida K, et al. Disrupted fat absorption attenuates obesity induced by a high-fat diet in Clock mutant mice. FEBS Lett 2006;580:127–130.
148. Zani F, Breasson L, Becattini B, Vukolic A, Montani JP, Albrecht U, et al. PER2 promotes glucose storage to liver glycogen during feeding and acute fasting by inducing Gys2 PTG and GL expression. Mol Metab 2013;2:292–305.
149. Martin RJ. Nocturnal asthma: circadian rhythms and therapeutic interventions. Am Rev Respir Dis 1993;147(6 Pt 2):S25–S28.
150. Nosal C, Ehlers A, Haspel JA. Why lungs keep time: circadian rhythms and lung immunity. Annu Rev Physiol 2020;82:391–412.
151. Sundar IK, Yao H, Sellix MT, Rahman I. Circadian molecular clock in lung pathophysiology. Am J Physiol Lung Cell Mol Physiol 2015;309:L1056–L1075.
152. Gibbs JE, Beesley S, Plumb J, Singh D, Farrow S, Ray DW, et al. Circadian timing in the lung; a specific role for bronchiolar epithelial cells. Endocrinology 2009;150:268–276.
153. Druzd D, Matveeva O, Ince L, Harrison U, He W, Schmal C, et al. Lymphocyte circadian clocks control lymph node trafficking and adaptive immune responses. Immunity 2017;46:120–132.
154. Shimba A, Ikuta K. Glucocorticoids regulate circadian rhythm of innate and adaptive immunity. Front Immunol 2020;11:2143.
155. Huang H, Jiang X, Du Q, Liao H, Cai S, Dong H. Circadian clock disruption and non-type 2 asthma: a hypothesis-driven perspective on immune, epithelial, and steroid response. Clin Rev Allergy Immunol 2025;68:72.
156. Pincus DJ, Szefler SJ, Ackerson LM, Martin RJ. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1995;95:1172–1178.
157. Lee Y, Field JM, Sehgal A. Circadian rhythms, disease and chronotherapy. J Biol Rhythms 2021;36:503–531.
158. Richardson C, Cain N, Bartel K, Micic G, Maddock B, Gradisar M. A randomised controlled trial of bright light therapy and morning activity for adolescents and young adults with delayed sleep-wake phase disorder. Sleep Med 2018;45:114–123.
159. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An update for 2015: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2015;11:1199–1236.
160. Golden RN, Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005;162:656–662.
161. Pail G, Huf W, Pjrek E, Winkler D, Willeit M, Praschak-Rieder N, et al. Bright-light therapy in the treatment of mood disorders. Neuropsychobiology 2011;64:152–162.
162. Lyall LM, Wyse CA, Graham N, Ferguson A, Lyall DM, Cullen B, et al. Association of disrupted circadian rhythmicity with mood disorders, subjective wellbeing, and cognitive function: a cross-sectional study of 91105 participants from the UK Biobank. Lancet Psychiatry 2018;5:507–514.
163. Figueiro MG, Plitnick BA, Lok A, Jones GE, Higgins P, Hornick TR, et al. Tailored lighting intervention improves measures of sleep, depression, and agitation in persons with Alzheimer’s disease and related dementia living in long-term care facilities. Clin Interv Aging 2014;9:1527–1537.
164. Wilkinson MJ, Manoogian ENC, Zadourian A, Lo H, Fakhouri S, Shoghi A, et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metab 2020;31:92–104.e5.
165. Lowe DA, Wu N, Rohdin-Bibby L, Moore AH, Kelly N, Liu YE, et al. Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity: the TREAT randomized clinical trial. JAMA Intern Med 2020;180:1491–1499.
166. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and metaanalysis. Ann Intern Med 2015;163:191–204.
167. Huang T. Sleep irregularity, circadian disruption, and cardiometabolic disease risk. Circ Res 2025;137:709–726.

Article information Continued

Figure 1.

Circadian disruption as a common mechanistic framework for chronic disease and cancer. ALAN, artificial light at night; ROS, reactive oxygen species; HPA, hypothalamic–pituitary–adrenal.

Table 1.

Circadian mechanisms linking chronic disease and antitumor immunity

Axis (core mechanism) Chronic disease readout Cancer/antitumor readout Evidence tier Translational implication Refs
Inflammatory/immune. CVD. Elevated IL-6, elevated CRP, and increased carotid intima-media thickness in night-shift workers Sleep restriction depletes tumor-infiltrating T cells; shifts cytokines away from Th1 Disease: observational (human). Cancer: preclinical (mouse) Rationale for evaluating sleep preservation during immunotherapy; leukocyte rhythm remains an unvalidated biomarker [17-22,25,26,118-120]
BMAL1-dependent NLRP3 inflammasome control; circadian leukocyte trafficking
Metabolic disruption. BMAL1/CLOCK control of insulin signaling and hepatic glucose output T2D. 47% reduction in insulin sensitivity with combined sleep loss and circadian misalignment CLOCK–ACSL1 stabilization drives cancer stemness (lung, mouse); inverse correlation with sleep quality (human tumor tissue) Disease: experimental (human). Cancer: preclinical (mouse)+correlative (human tissue) Time-restricted eating as adjunct metabolic intervention; CLOCK–ACSL1 targeting remains exploratory [28,30,32,35-37,39,139]
Oxidative stress and genomic instability. Circadian gating of DNA repair and cell-cycle checkpoints OA. Bmal1 loss drives mTORC1-mediated cartilage degeneration; clock decline precedes structural damage HSF1 signaling increases tumor burden in Kras-driven lung cancer (mouse) Disease: preclinical (mouse)+correlative (human tissue). Cancer: preclinical (mouse) Central mechanistic rationale for chronotherapy; no validated predictive biomarker yet [5,44,47,50-53,55-57,59,124,128,129]
Neuroendocrine. SCN control of HPA axis; AANAT-mediated melatonin secretion Asthma. Cortisol nadir coincides with nocturnal symptom peak; timed corticosteroids improve control Melatonin–ALAN hypothesis for breast cancer risk; human evidence inconsistent Disease: experimental (human)+RCT. Cancer: preclinical (mouse)+observational (human, conflicting) Timed corticosteroid dosing is already actionable; nocturnal light avoidance is low-risk but unproven for cancer prevention [62-64,69,73,78,152,154]
Tumor-intrinsic clock dysregulation following malignant transformation. Clock control of oncogene/tumor-suppressor expression Not applicable—confined to transformed cells Chronomodulated chemotherapy improves tolerability, not response (7 RCTs); afternoon-only ICI dosing linked to shorter survival (retrospective, n=121) Cancer: RCT meta-analysis (chemotherapy)+retrospective cohort (immunotherapy) Chemotherapy timing is the most clinically mature intervention—benefit limited to reduced toxicity, not survival; immunotherapy timing remains investigational [5,39,92,94-97,109,115,165,166]

Evidence tiers follow the four-level classification introduced in Methods: mechanistic/in vitro, preclinical (animal), observational/retrospective (human), and prospective/randomized (human). Ref, reference; CVD, cardiovascular disease; CRP, C-reactive protein; T2D, type 2 diabetes mellitus; OA, osteoarthritis; HSF1, heat shock factor 1; SCN, suprachiasmatic nucleus; HPA, hypothalamic–pituitary–adrenal; ALAN, artificial light at night; RCT, randomized controlled trial; ICI, immune checkpoint inhibitor.